Header

UZH-Logo

Maintenance Infos

The role of small, dense LDL in cardiovascular risk: The contributions of the universities of Palermo and Zurich


Rizzo, M; Berneis, K (2010). The role of small, dense LDL in cardiovascular risk: The contributions of the universities of Palermo and Zurich. Frontiers in Cardiovascular Drug Discovery, 1:96-104.

Abstract

Low density lipoproteins (LDL) size seems to be an important predictor of cardiovascular events and progression of coronary artery disease and the predo-minance of small dense LDL has been accepted as an emerging cardiovascular risk factors by the National Cholesterol Education Program Adult Treatment Panel III. We recently showed increased LDL size or higher levels of small and dense LDL in different categories of patients at higher cardiovascular risk, such as those with coronary (including acute myocardial infarction) and non-coronary (including carotid disease, abdominal aortic aneurysm and peripheral arterial disease) forms of atherosclerosis or metabolic diseases (including type-II diabetes, polycystic ovary syndrome, growth hormone deficiency, gestational diabetes and the metabolic syndrome). Screening for the presence of small, dense LDL may potentially identify those with even higher risks and may contribute in directing specific treatments in order to prevent new cardiovascular events. This seems particularly true for statins and fibrates. Promising data are available for rosuvastatin, the latest statin molecule introduced in the market, and ezetimibe, a cholesterol absorption inhibitor.

Abstract

Low density lipoproteins (LDL) size seems to be an important predictor of cardiovascular events and progression of coronary artery disease and the predo-minance of small dense LDL has been accepted as an emerging cardiovascular risk factors by the National Cholesterol Education Program Adult Treatment Panel III. We recently showed increased LDL size or higher levels of small and dense LDL in different categories of patients at higher cardiovascular risk, such as those with coronary (including acute myocardial infarction) and non-coronary (including carotid disease, abdominal aortic aneurysm and peripheral arterial disease) forms of atherosclerosis or metabolic diseases (including type-II diabetes, polycystic ovary syndrome, growth hormone deficiency, gestational diabetes and the metabolic syndrome). Screening for the presence of small, dense LDL may potentially identify those with even higher risks and may contribute in directing specific treatments in order to prevent new cardiovascular events. This seems particularly true for statins and fibrates. Promising data are available for rosuvastatin, the latest statin molecule introduced in the market, and ezetimibe, a cholesterol absorption inhibitor.

Statistics

Altmetrics

Downloads

2 downloads since deposited on 09 Feb 2011
0 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, further contribution
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Endocrinology and Diabetology
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2010
Deposited On:09 Feb 2011 18:58
Last Modified:07 Dec 2017 07:10
Publisher:Bentham Science
ISSN:1879-6648
Additional Information:eISBN: 978-1-60805-160-1
Publisher DOI:https://doi.org/10.2174/978160805160111001010096
Official URL:http://www.benthamscience.com/ebooks/9781608051601/contents.htm

Download